J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

 
• By Alaric DeArment
J&J CEO Joaquin Duato spoke about the company's acquisition of Ambrx at the J.P. Morgan Healthcare Conference • Source: Shutterstock

More from Deals

More from Business